See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
International Women's Day
Artificial Intelligence
Tariffs
US Economy
Donald Trump
Social Media
Newspaper Front Pages
Basketball
European Union
Stock Markets
Music
Republican Party
Published • loading... • Updated

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

  • Akeso announced the completion of patient enrollment for its Phase III clinical trial of cadonilimab, a bispecific antibody for high-risk recurrent hepatocellular carcinoma .
  • Cadonilimab is the world's first PD-1/CTLA-4 bispecific antibody developed by Akeso for HCC, which has a high recurrence rate after surgery.
  • Research at the 2023 ESMO meetings showed cadonilimab's effectiveness, achieving a 100% disease control rate in neoadjuvant therapy for resectable multinodular HCC.
  • Akeso is committed to further advancing cadonilimab's clinical development and currently has over 23 clinical studies in progress across multiple cancer types, aiming to improve patient outcomes worldwide.
Insights by Ground AI
Does this summary seem wrong?

43 Articles

All
Left
5
Center
11
Right
4
The Laconia Daily SunThe Laconia Daily Sun
+41 Reposted by 41 other sources

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

HONG KONG, March 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world's first PD-1/CTLA-4 bispecific antibody…

Read Full Article
myscience.orgmyscience.org

Transplantation combined with immunotherapy to cure liver cancer

6.03.2025 - A study led by the University of Geneva and the HUG shows that an interval of at least 50 days between stopping immunotherapy and liver transplantation significantly reduces the risk of rejection. Hepatocellular carcinoma (HCC) is the most common type of liver cancer in Switzerland and worldwide.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 55% of the sources are Center
55% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Charleston Gazette-Mail broke the news in Charleston, United States on Thursday, March 6, 2025.
Sources are mostly out of (0)

Similar News Topics

China

China

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal